Literature DB >> 8302603

Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor).

P Longati1, A Bardelli, C Ponzetto, L Naldini, P M Comoglio.   

Abstract

The tyrosine kinase encoded by the MET proto-oncogene (p190MET) is the receptor for Hepatocyte Growth Factor/Scatter Factor (HGF/SF). Previous work has shown that autophosphorylation of p190MET enhances its enzymatic activity and that the major phosphorylation site is Tyr1235, located in the catalytic domain. This residue is part of a 'three tyrosine' motif, including Tyr1230, Tyr1234, and Tyr1235, conserved in several other receptor kinases. We studied the role of these tyrosines in the positive regulation of the p190MET kinase by site-directed mutagenesis. Substitution of either Tyr1235 or Tyr1234 with phenylalanine severely reduced the in vitro kinase activity toward exogenous substrates. Kinetic experiments showed that the residual activity of these mutants could still be enhanced by autophosphorylation. Phosphopeptide mapping indicated that, in the absence of Tyr1235, Tyr1234 is phosphorylated. Only the replacement of both Tyr1234 and Tyr1235 yielded a mutant which completely lost the ability to be activated by autophosphorylation. In stable transfectants expressing the HGF/SF receptor with single substitution of either Tyr1234 or Tyr1235 the response to HGF/SF was impaired. The ligand did not induce tyrosine phosphorylation of the receptor nor stimulated chemotaxis. These data show that Tyr1234 and Tyr1235 are critical for the activation of the HGF/SF receptor kinase both in vitro and in response to the ligand in intact cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8302603

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  60 in total

1.  Functional co-operation between the subunits in heterodimeric platelet-derived growth factor receptor complexes.

Authors:  M Emaduddin; S Ekman; L Rönnstrand; C H Heldin
Journal:  Biochem J       Date:  1999-08-01       Impact factor: 3.857

2.  The multisubstrate docking site of the MET receptor is dispensable for MET-mediated RAS signaling and cell scattering.

Authors:  D Tulasne; R Paumelle; K M Weidner; B Vandenbunder; V Fafeur
Journal:  Mol Biol Cell       Date:  1999-03       Impact factor: 4.138

3.  Combined systemic elimination of MET and epidermal growth factor receptor signaling completely abolishes liver regeneration and leads to liver decompensation.

Authors:  Shirish Paranjpe; William C Bowen; Wendy M Mars; Anne Orr; Meagan M Haynes; Marie C DeFrances; Silvia Liu; George C Tseng; Anastasia Tsagianni; George K Michalopoulos
Journal:  Hepatology       Date:  2016-10-01       Impact factor: 17.425

4.  Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog.

Authors:  S R Hubbard
Journal:  EMBO J       Date:  1997-09-15       Impact factor: 11.598

5.  Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis.

Authors:  Bénédicte Foveau; Frédéric Ancot; Catherine Leroy; Annalisa Petrelli; Karina Reiss; Valérie Vingtdeux; Silvia Giordano; Véronique Fafeur; David Tulasne
Journal:  Mol Biol Cell       Date:  2009-03-18       Impact factor: 4.138

6.  Synergistic activities of multiple phosphotyrosine residues mediate full signaling from the Drosophila Torso receptor tyrosine kinase.

Authors:  U Gayko; V Cleghon; T Copeland; D K Morrison; N Perrimon
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

7.  Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?

Authors:  Teresa Troiani; Erika Martinelli; Floriana Morgillo; Anna Capasso; Anna Nappi; Vincenzo Sforza; Fortunato Ciardiello
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

Review 8.  Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.

Authors:  Ralph E Parchment; James H Doroshow
Journal:  Semin Oncol       Date:  2016-07-26       Impact factor: 4.929

9.  A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype.

Authors:  C Collesi; M M Santoro; G Gaudino; P M Comoglio
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

Review 10.  The multiple paths towards MET receptor addiction in cancer.

Authors:  Leslie Duplaquet; Zoulika Kherrouche; Simon Baldacci; Philippe Jamme; Alexis B Cortot; Marie-Christine Copin; David Tulasne
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.